All In Biotech

Drug Trial Radar · NCT05161936

A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Lumasiran in Patients With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels

Last checked: Nov 20, 2026Latest source record: May 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

2

Actual

Start

Jan 27, 2022

Primary completion

Nov 1, 2022

Study completion Nov 1, 2022

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Dec 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the effect of lumasiran on the percent change in urinary oxalate excretion in patients with recurrent calcium oxalate kidney stone disease.

Conditions

  • Recurrent Calcium Oxalate Kidney Stone Disease
  • Elevated Urinary Oxalate Levels

Interventions

  • LumasiranDrug

    Lumasiran will be administered by SC injection.

  • PlaceboDrug

    Placebo will be administered by SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in 24-hour Urinary Oxalate From Baseline to Month 6Time frame: Baseline to Month 6

Locations

31 sites in 6 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Birmingham, Alabama

  • Clinical Trial Site

    Northridge, California

  • Clinical Trial Site

    San Francisco, California

  • Clinical Trial Site

    Hialeah, Florida

  • Clinical Trial Site

    Acworth, Georgia

  • Clinical Trial Site

    Quincy, Illinois

  • Clinical Trial Site

    Carmel, Indiana

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Edina, Minnesota

  • Clinical Trial Site

    Rochester, Minnesota

  • Clinical Trial Site

    Las Vegas, Nevada

  • Clinical Trial Site

    Albany, New York

  • Clinical Trial Site

    Garden City, New York

  • Clinical Trial Site

    Greensboro, North Carolina

  • Clinical Trial Site

    North Charleston, South Carolina

  • Clinical Trial Site

    El Paso, Texas

  • Clinical Trial Site

    Houston, Texas

  • Clinical Trial Site

    Brussels, Belgium

  • Clinical Trial Site

    Ghent, Belgium

  • Clinical Trial Site

    Kortrijk, Belgium

  • Clinical Trial Site

    Liège, Belgium

  • Clinical Trial Site

    Bologna, Italy

  • Clinical Trial Site

    Pavia, Italy

  • Clinical Trial Site

    Rome, Italy

  • Clinical Trial Site

    Verona, Italy

  • Clinical Trial Site

    Madrid, Spain

  • Clinical Trial Site

    Bern, Switzerland

  • Clinical Trial Site

    Lausanne, Switzerland

  • Clinical Trial Site

    Zurich, Switzerland

  • Clinical Trial Site

    Doncaster, United Kingdom

  • Clinical Trial Site

    Leeds, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.